The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children’s Oncology Group study.
Michael J. Borowitz
Research Funding - Becton-Dickinson
Brent L. Wood
Research Funding - Becton-Dickinson
Meenakshi Devidas
No relevant relationships to disclose
Mignon L. Loh
No relevant relationships to disclose
Elizabeth A. Raetz
No relevant relationships to disclose
Eric Larsen
No relevant relationships to disclose
Kelly W. Maloney
No relevant relationships to disclose
Andrew J Carroll
No relevant relationships to disclose
Alison M. Friedmann
No relevant relationships to disclose
Julie M Gastier-Foster
No relevant relationships to disclose
Nyla A. Heerema
No relevant relationships to disclose
Leonard A. Mattano
No relevant relationships to disclose
James B. Nachman
No relevant relationships to disclose
Naomi Joan Winick
No relevant relationships to disclose
William L. Carroll
No relevant relationships to disclose
Stephen Hunger
No relevant relationships to disclose